Verismo Therapeutics Establishes R&D Center in Philadelphia to Drive KIR-CAR Platform Forward

Verismo Therapeutics Establishes R&D Center in Philadelphia to Drive KIR-CAR Platform Forward
Verismo Therapeutics Receives U.S. FDA Orphan Drug Designation for SynKIR-110™, a First-in-Class KIR-CAR T Cell Immunotherapy Candidate, for the Treatment of Mesothelioma
Verismo Therapeutics Announces FDA Clearance of IND Application for SynKIR-110™, a KIR-CAR T Cell Immunotherapy Candidate
Verismo Therapeutics Announces Submission of IND Application to the FDA for SynKIR-110™, a KIR-CAR T-cell Immunotherapy Candidate
Verismo Therapeutics Announces Research Partnership with the University of Pennsylvania
Verismo Therapeutics Expands Scientific Team to Advance its KIR-CAR Platform for the Treatment of Solid Tumors
Biopharma charts progress in translating CAR-T cell therapies to solid cancers
Verismo Therapeutics Appoints Steven Albelda, MD, to Scientific Advisory Board
Verismo Therapeutics Appoints Laura Johnson, Ph.D. as Chief Scientific Officer